PL4313994T3 - Pochodne tetrahydrotienopirydyny jako inhibitory DDR - Google Patents

Pochodne tetrahydrotienopirydyny jako inhibitory DDR

Info

Publication number
PL4313994T3
PL4313994T3 PL22717822.5T PL22717822T PL4313994T3 PL 4313994 T3 PL4313994 T3 PL 4313994T3 PL 22717822 T PL22717822 T PL 22717822T PL 4313994 T3 PL4313994 T3 PL 4313994T3
Authority
PL
Poland
Prior art keywords
ddrs
inhibitors
pyridine derivatives
tetrahydrothieno
tetrahydrothieno pyridine
Prior art date
Application number
PL22717822.5T
Other languages
English (en)
Inventor
Laura Carzaniga
Fabio Rancati
Andrea Rizzi
Keith Christopher KNIGHT
Anna KARAWAJCZYK
Barbara Karolina Wolek
Toby Matthew Grover MULLINS
Ben Paul WHITTAKER
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL4313994T3 publication Critical patent/PL4313994T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL22717822.5T 2021-03-26 2022-03-25 Pochodne tetrahydrotienopirydyny jako inhibitory DDR PL4313994T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21165284 2021-03-26
PCT/EP2022/057940 WO2022200578A1 (en) 2021-03-26 2022-03-25 Tetrahydrothieno pyridine derivatives as ddrs inhibitors

Publications (1)

Publication Number Publication Date
PL4313994T3 true PL4313994T3 (pl) 2025-06-23

Family

ID=75252445

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22717822.5T PL4313994T3 (pl) 2021-03-26 2022-03-25 Pochodne tetrahydrotienopirydyny jako inhibitory DDR

Country Status (11)

Country Link
EP (1) EP4313994B1 (pl)
JP (1) JP2024510849A (pl)
KR (1) KR20230163465A (pl)
CN (1) CN117098764A (pl)
AU (1) AU2022242770A1 (pl)
BR (1) BR112023019457A2 (pl)
CA (1) CA3212769A1 (pl)
ES (1) ES3029708T3 (pl)
MX (1) MX2023011058A (pl)
PL (1) PL4313994T3 (pl)
WO (1) WO2022200578A1 (pl)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003073357A (ja) * 2001-09-03 2003-03-12 Mitsubishi Pharma Corp アミド化合物を含有するＲｈｏキナーゼ阻害剤
CN105658635B (zh) * 2014-08-22 2019-03-08 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用
AU2015335980A1 (en) 2014-10-22 2017-05-18 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
CN104490889B (zh) * 2014-12-30 2016-04-20 中国人民解放军第四军医大学 一种 ddr2 小分子抑制剂抗肺纤维化应用
JP7002335B2 (ja) * 2015-07-03 2022-01-20 エフ．ホフマン－ラ ロシュ アーゲー Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
WO2019182274A1 (en) * 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
CN108558848A (zh) * 2018-04-19 2018-09-21 华东师范大学 一种环烷烃并噻吩衍生物及其制备方法和医药用途
KR20200087922A (ko) * 2019-01-11 2020-07-22 보로노이바이오 주식회사 (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
CN117157300A (zh) * 2021-03-26 2023-12-01 奇斯药制品公司 作为ddr抑制剂的四氢噻吩并吡啶衍生物

Also Published As

Publication number Publication date
WO2022200578A8 (en) 2023-09-07
EP4313994A1 (en) 2024-02-07
ES3029708T3 (en) 2025-06-25
CN117098764A (zh) 2023-11-21
AU2022242770A1 (en) 2023-11-09
WO2022200578A1 (en) 2022-09-29
EP4313994B1 (en) 2025-03-05
US20240199635A1 (en) 2024-06-20
JP2024510849A (ja) 2024-03-11
KR20230163465A (ko) 2023-11-30
CA3212769A1 (en) 2022-09-29
BR112023019457A2 (pt) 2023-12-05
MX2023011058A (es) 2023-09-28

Similar Documents

Publication Publication Date Title
IL310403A (en) Converted pyridine derivatives as SARM1 inhibitors
ZA201904737B (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
IL263404B (en) History of ring-fused bicyclic pyridyls as fgfr4 inhibitors
SG11202011165TA (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
ZA201808257B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
CA3256849A1 (en) Synchronization signal transmission for mobility
SMT201700317T1 (it) Derivati piridinici in qualità di inibitori rock teneri
IL258341A (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
EP3858834A4 (en) PYRAZOLOPYRIMIDE DERIVATIVES AS SELECTIVE TRK INHIBITORS
PL4396183T3 (pl) Podstawione pochodne s-alaninianu
IL288950A (en) History of pyridine-3-yl
PT4313293T (pt) Derivados de tetraidrotieno piridina como inibidores de ddrs
LT4313293T (lt) Tetrahidrotieno piridino dariniai kaip ddr inhibitoriai
PL4313994T3 (pl) Pochodne tetrahydrotienopirydyny jako inhibitory DDR
IL281811A (en) Thiano[3,2-B]pyridine derivatives as UPD glycosyltransferase inhibitors and methods of use
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
HK40110746A (en) Substituted pyridine derivatives as sarm1 inhibitors
HK40068930A (en) Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors
CA3294653A1 (en) Heteroaryl derivatives as ddrs inhibitors
HK40060820B (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物
HK40041290A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40113674A (en) Sestrin-mapk complex inhibitors
HK40080738A (en) Tricyclic heterocycles as fgfr inhibitors